BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38474320)

  • 1. Identification of Key Molecular Pathways and Associated Genes as Targets to Overcome Radiotherapy Resistance Using a Combination of Radiotherapy and Immunotherapy in Glioma Patients.
    Zhang T; Zhang Q; He X; Lu Y; Shao A; Sun X; Shao Y
    Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of a prognostic gene expression signature for lower-grade glioma following surgery and adjuvant radiotherapy.
    Qian DC; Marascio JA; Tobillo R; Lorenz JW; McCall NS; Neill SG; Hoang KB; Olson JJ; Eaton BR; Shu HG; Zhong J
    Radiother Oncol; 2022 Oct; 175():93-100. PubMed ID: 35998839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicellular biomarkers of drug resistance as promising targets for glioma precision medicine and predictors of patient survival.
    Lu Y; Shao Y
    Cancer Drug Resist; 2022; 5(2):511-533. PubMed ID: 35800363
    [No Abstract]   [Full Text] [Related]  

  • 4. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
    Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
    Front Immunol; 2022; 13():899710. PubMed ID: 35677036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Prognostic Microenvironment-Related Immune Signature
    Qiu H; Li Y; Cheng S; Li J; He C; Li J
    Front Oncol; 2020; 10():580263. PubMed ID: 33425732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The molecular feature of macrophages in tumor immune microenvironment of glioma patients.
    Zhang H; Luo YB; Wu W; Zhang L; Wang Z; Dai Z; Feng S; Cao H; Cheng Q; Liu Z
    Comput Struct Biotechnol J; 2021; 19():4603-4618. PubMed ID: 34471502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
    Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
    Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR-cas9 screening identified lethal genes enriched in Hippo kinase pathway and of predictive significance in primary low-grade glioma.
    Mijiti M; Maimaiti A; Chen X; Tuersun M; Dilixiati M; Dilixiati Y; Zhu G; Wu H; Li Y; Turhon M; Abulaiti A; Maimaitiaili N; Yiming N; Kasimu M; Wang Y
    Mol Med; 2023 May; 29(1):64. PubMed ID: 37183261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
    Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
    BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Value of a Stemness Index-Associated Signature in Primary Lower-Grade Glioma.
    Zhang M; Wang X; Chen X; Guo F; Hong J
    Front Genet; 2020; 11():441. PubMed ID: 32431729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complement and coagulation cascades are associated with prognosis and the immune microenvironment of lower-grade glioma.
    Yang J; Shen L; Yang J; Qu Y; Gong C; Zhou F; Liu Y; Luo M; Zhao L
    Transl Cancer Res; 2024 Jan; 13(1):112-136. PubMed ID: 38410234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Immune-Related Gene Signature for Risk Stratification and Prognosis of Survival in Lower-Grade Glioma.
    Zhang M; Wang X; Chen X; Zhang Q; Hong J
    Front Genet; 2020; 11():363. PubMed ID: 32351547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An autophagic gene-based signature to predict the survival of patients with low-grade gliomas.
    Chen J; Li Y; Han X; Pan Y; Qian X
    Cancer Med; 2021 Mar; 10(5):1848-1859. PubMed ID: 33591634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Single-cell transcriptome analysis of multigrade glioma heterogeneity and immune microenvironment revealed potential prognostic biomarkers].
    Liu J; Xu K; Ma L; Wang Y
    Sheng Wu Gong Cheng Xue Bao; 2022 Oct; 38(10):3790-3808. PubMed ID: 36305410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ECM2, a prognostic biomarker for lower grade glioma, serves as a potential novel target for immunotherapy.
    Cheng X; Liu Z; Liang W; Zhu Q; Wang C; Wang H; Zhang J; Li P; Gao Y
    Int J Biochem Cell Biol; 2023 May; 158():106409. PubMed ID: 36997057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive Characterization of a Novel E3-Related Gene Signature With Implications in Prognosis and Immunotherapy of Low-Grade Gliomas.
    Tan S; Spear R; Zhao J; Sun X; Wang P
    Front Genet; 2022; 13():905047. PubMed ID: 35832194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and Validation of an Energy Metabolism-Related lncRNA-mRNA Signature for Lower-Grade Glioma.
    Zhao J; Wang L; Wei B
    Biomed Res Int; 2020; 2020():3708231. PubMed ID: 32802843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EFNA1 is a potential key gene that correlates with immune infiltration in low-grade glioma.
    Hao YP; Wang WY; Qiao Q; Li G
    Medicine (Baltimore); 2021 Jun; 100(22):e26188. PubMed ID: 34087884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Systematic Landscape of Nectin Family and Nectin-Like Molecules: Functions and Prognostic Value in Low Grade Glioma.
    Han Y; Zou C; Zhu C; Liu T; Shen S; Cheng P; Cheng W; Wu A
    Front Genet; 2021; 12():718717. PubMed ID: 34925438
    [No Abstract]   [Full Text] [Related]  

  • 20. A Novel 10-Gene Signature Predicts Poor Prognosis in Low Grade Glioma.
    Liu W; Zou J; Ren R; Liu J; Zhang G; Wang M
    Technol Cancer Res Treat; 2021; 20():1533033821992084. PubMed ID: 33550903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.